Core Viewpoint - OKYO Pharma has appointed Leerink Partners as the new sales agent for its At-The-Market (ATM) equity offering, transitioning from B. Riley Securities, to enhance its financial flexibility and support ongoing clinical development [2][3][4]. Group 1: Appointment of Sales Agent - OKYO Pharma Ltd has transitioned its ATM equity offering facility to Leerink Partners, replacing B. Riley Securities as the exclusive sales agent [2][3]. - Leerink Partners will facilitate the sale of common shares directly into the market at prevailing prices, depending on market conditions and company discretion [3]. Group 2: Purpose and Benefits of ATM Facility - The ATM facility is designed to provide OKYO Pharma with the flexibility to raise capital opportunistically while minimizing market disruption [4]. - The CFO of OKYO Pharma emphasized that this transition enhances financial flexibility to support ongoing clinical development and corporate objectives without committing to a fixed equity raise [5]. Group 3: Financial Terms - Leerink Partners will receive a commission of 3% of gross proceeds from any shares sold under the ATM program [6].

Core Insights - OKYO Pharma Limited has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, enhancing its ability to access capital markets efficiently [1][2] - The new partnership with Leerink Partners is expected to provide financial flexibility to support ongoing clinical development, particularly for its lead candidate urcosimod for neuropathic corneal pain [2] Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares listed on the Nasdaq Capital Market [4] - The company recently completed a successful Phase 2 trial of urcosimod and plans to initiate a Phase 2b/3 multiple-dose study involving approximately 150 subjects in the first half of the year [4]

分组1: Company Earnings - Spotify Technology SA reported fourth-quarter revenue growth of 13% year-on-year on a constant-currency basis, exceeding earnings expectations despite mixed revenue comparisons [1] - Marriott International Inc posted fourth-quarter revenue of $6.69 billion, slightly beating estimates, although adjusted EPS came in just below consensus [1] - The Coca-Cola Company experienced a 2.8% decline in shares after reporting its first quarterly revenue miss in five years, despite adjusted EPS of $0.58 beating forecasts [2] - Ferrari reported fourth-quarter net revenue of €1.8 billion, exceeding market expectations, leading to a 9% increase in shares [2] - Datadog Inc's shares jumped 16% after reporting fourth-quarter revenue up 29% year-on-year to $953 million, with non-GAAP EPS of $0.59, both surpassing Wall Street expectations [3] - ON Semiconductor posted fourth-quarter earnings with revenue of $1.53 billion, aligning with estimates despite a decline from the previous year [2] 分组2: Market Trends and Economic Indicators - The Dow finished at 50,188, up 52 points or 0.1%, while the S&P 500 fell 23 points, or 0.3%, indicating mixed market performance [7] - Consumer spending appears to be slowing, aligning with weak consumer sentiment, as December retail sales came in flat against expectations of a 0.4% rise [11][18] - The NFIB Small Business Optimism index slipped in January, ending a two-month streak of gains, with fewer firms expecting economic improvement [13] - The US Employment Cost Index rose 0.7% in Q4, slightly below the 0.8% forecast, indicating a moderating labor market [18][19] - Investors are focusing on upcoming economic reports, including the January jobs report, which is expected to provide clarity on labor market conditions [6][24]

FDA Approvals & Rejections - Intellia Therapeutics has received FDA approval to resume its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) targeting hereditary transthyretin amyloidosis with polyneuropathy, increasing target enrollment from 50 to 60 patients [2][4] - Outset Medical's next-generation Tablo Hemodialysis System has been granted FDA 510(k) clearance, making it the first dialysis device to meet enhanced cybersecurity standards, with shipping expected to begin in Q2 2026 [6][7] - OKYO Pharma has received positive feedback from the FDA for its Phase 2b/3 trial design for Urcosimod, a candidate for neuropathic corneal pain, with plans to start the trial in the first half of 2026 [8][9] - REGENXBIO has faced clinical holds on its RGX-111 and RGX-121 gene therapy programs due to a case of CNS tumor in a child treated with RGX-111, although no similar findings were reported in other patients [10][11] - Almirall has received NMPA approval for Seysara in China for treating moderate-to-severe acne vulgaris, expanding its dermatology portfolio in the region [12][13] Clinical Trials - Breakthroughs - Aprea Therapeutics reported early clinical activity for APR-1051 in endometrial cancer, achieving a 50% reduction in target lesion size in a patient with PPP2R1A-mutated uterine serous carcinoma [19][21] - Fractyl Health's Revita demonstrated positive results in weight maintenance after GLP-1 drug discontinuation, showing a 4.5% weight regain compared to 7.5% in the sham group [22][24] - Ascletis Pharma announced positive Phase 3 results for Denifanstat in moderate-to-severe acne vulgaris, focusing on long-term safety in a trial with 240 patients [25][26] - GRI Bio reported new gene expression data from its Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis, showing significant improvements in lung injury and fibrosis progression [27][28] - Cardiff Oncology announced encouraging results from its Phase 2 trial of Onvansertib in RAS-mutated metastatic colorectal cancer, with a well-tolerated regimen and plans to advance to a registrational program [31][32] - Genentech's CT-388 Phase 2 trial for obesity showed a significant placebo-adjusted weight loss of 22.5% at 48 weeks, with a high percentage of participants achieving significant weight loss [34][36] - Sarepta Therapeutics reported positive three-year results from its EMBARK study for ELEVIDYS in Duchenne muscular dystrophy, showing significant slowing of disease progression in treated patients [38][41] Deals - YD Bio Limited has signed a letter of intent to acquire Safe Save Medical for approximately $26.87 million, aiming to enhance its capabilities in advanced cellular therapeutics [14][15][17]

Core Insights - Biotech companies experienced significant gains in after-hours trading, driven by investor interest despite limited news catalysts [1] Company Updates - GH Research PLC (GHRS) saw the largest increase, rising 22.36% to $16.20 ahead of a key update on its Investigational New Drug Application (IND) for GH001 with the FDA, scheduled for January 5, 2026 [2] - Phathom Pharmaceuticals, Inc. (PHAT) increased by 5.03% to $16.50, with the rise attributed to investor positioning rather than new announcements [3] - Forte Biosciences, Inc. (FBRX) gained 3.56%, closing at $24.45, continuing its upward trend in the biotech sector without any new updates [3] - OKYO Pharma Limited (OKYO) advanced 5.38% to $2.35, influenced by prior disclosures regarding share acquisitions by its Executive Chairman [4] - Zai Lab Limited (ZLAB) rose 5.60% to $18.30, reflecting ongoing investor interest in international biotech firms [5] - LifeMD, Inc. (LFMD) added 3.15% to $3.60, with no corporate updates released [5] - Werewolf Therapeutics, Inc. (HOWL) climbed 3.58% to $0.67, indicating speculative interest in smaller-cap biotech stocks [6] - Corvus Pharmaceuticals, Inc. (CRVS) increased by 7.24% to $7.85, extending its upward momentum without any new announcements [6]

Core Insights - Several small-cap biotech and pharma companies experienced notable gains in after-hours trading, with Nutex Health being the most significant mover following its quarterly results [1] Company Summaries - **Nutex Health Inc. (NUTX)**: The company saw its stock surge by 20.97% to $120.00 after reporting a third-quarter net loss of $17.7 million, compared to a net loss of $0.4 million in the same period last year. However, total revenue increased significantly by 220.7% year-over-year to $244.0 million from $76.1 million [2] - **Bullfrog AI Holdings, Inc. (BFRG)**: The stock rose by 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of an upcoming technical presentation at the AI Drug Discovery & Development Summit 2025 [3] - **Clearside Biomedical, Inc. (CLSD)**: The company’s stock increased by 6.51% to $3.27 after reporting a narrower third-quarter net loss of $5.97 million compared to $7.69 million last year, although revenue fell sharply to $201 thousand from $1.04 million [4] - **Aytu BioPharma, Inc. (AYTU)**: The stock climbed 8.91% to $2.20, following a prior close of $2.02. The company reported a first-quarter net income of $2.0 million versus $1.5 million a year ago, with revenue of $13.9 million compared to $16.6 million in the prior year [5] - **Adicet Bio, Inc. (ACET)**: The stock added 5.21% to $0.6325, with a reported third-quarter net loss of $12.4 million, slightly wider than last year's $11.6 million. Revenue declined by 16% year-over-year to $6.8 million, but the company reiterated its 2025 revenue guidance [6] - **OKYO Pharma Limited (OKYO)**: The stock rose by 2.44% to $2.18. The CEO is scheduled to present at the Ophthalmology Innovation Summit XV, discussing the investigational drug candidate urcosimod, which has shown promising results in Phase 2 trials [7]

Core Insights - Several healthcare and biotech stocks experienced significant price movements on September 29, driven by clinical trial updates, regulatory progress, and strategic announcements Company Performance Highlights - Phio Pharmaceuticals Corp. (PHIO) saw an 8.9% increase in after-hours trading, rising from $2.36 to $2.57, following a 5.83% gain during the regular session, attributed to a positive safety committee recommendation for its PH-762 skin cancer trial [1][2] - Barinthus Biotherapeutics plc (BRNS) rose 8.11% in after-hours trading to $1.60 after closing at $1.48, with a notable 21.3% gain, driven by renewed interest in its immunotherapeutic pipeline [2][3] - Neogen Corp. (NEOG) jumped 5.59% in after-hours trading to $5.90, reversing a 1.41% decline earlier in the day, following announcements of its upcoming earnings release and a renewed sponsorship agreement [3][4] - OKYO Pharma Ltd. (OKYO) increased by 9% in after-hours trading to $2.18 after a decline of 8.26% during the regular session, due to renewed focus on its clinical-stage program for urcosimod [5] - Aurinia Pharmaceuticals Inc. (AUPH) rose 8.05% in after-hours trading to $11.95, despite a 15.83% drop earlier, reflecting heightened activity around its lupus nephritis treatment, LUPKYNIS, and a collaboration with Otsuka Pharmaceutical [6] - RAPT Therapeutics, Inc. (RAPT) climbed 4.43% in after-hours trading to $27.80, following the FDA's clearance of its IND application for RPT904, allowing it to proceed with a Phase 2b trial targeting food allergies [7][8]

Core Insights - OKYO Pharma Limited is developing urcosimod for treating neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED), with the latter being a multi-billion-dollar market [1][8] - Urcosimod has demonstrated stability for over two and a half years in single-use ampoules, which is crucial for FDA approval [1][6] - The company is currently conducting a Phase 2b clinical trial for urcosimod in NCP patients, involving 48 participants [3][7] Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on innovative therapies for NCP and DED, with shares traded on NASDAQ [8] - The company emphasizes the importance of chemistry, manufacturing, and controls (CMC) in drug approval processes, particularly regarding shelf stability [2] Clinical Development - The Phase 2b trial for urcosimod is a double-masked, randomized, placebo-controlled study, confirming NCP through confocal microscopy [3] - Urcosimod is administered as eye drops, and its stability and efficacy have been positively received in earlier trials for DED [2][5] Drug Characteristics - Urcosimod is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, designed to provide long-lasting effects in treating dry eye disease and corneal neuropathic pain [5] - The drug has shown anti-inflammatory and pain-reducing activities in preclinical models, enhancing its potential for clinical use [5]

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on June 9, 2023. Registration Statement No. 333-272005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to Form F-1 OKYO Pharma Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) OKYO Pharma Limited Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB +44 (0)20 7495 2379 (Address, ...